{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T18:49:43Z","timestamp":1740163783422,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"crossref","award":["81670104"],"award-info":[{"award-number":["81670104"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin Health Science and Technology Project","award":["ZC20171"],"award-info":[{"award-number":["ZC20171"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81800148","81870150"],"award-info":[{"award-number":["81800148","81870150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>High-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (ASCT) is still a consolidation treatment choice for relapsed\/refractory B-cell non-Hodgkin\u2019s lymphoma (NHL) patients and some aggressive B-cell NHL as frontline therapy. Due to the shortage of carmustine, we switched to idarubicin-substituted BEAC (IEAC) conditioning regimen. We retrospectively compared the outcomes of 72 aggressive B-cell NHL patients treated with IEAC or BEAC regimens followed by ASCT as upfront consolidative treatment. The median time to neutrophil and platelet reconstitution showed no difference between IEAC and BEAC groups. IEAC regimen was well tolerated without increase of adverse events. Transplant-related mortality didn\u2019t occur. The overall survival (OS) and progression-free survival (PFS) of IEAC group (33 and 23\u00a0months) were a little longer than that of BEAC group (30 and 18\u00a0months). However, due to the small sample numbers, there\u2019s no significant difference in OS and PFS between IEAC and BEAC group with DLBCL or MCL. Multivariate analysis showed that AnnArbor staging, IPI score, lactate dehydrogenase level, remission of disease, modified regimen were related with PFS and OS. In conclusion, IEAC regimen was well tolerated and replacement with idarubicin could be an alternative when carmustine was not available.<\/jats:p>","DOI":"10.1038\/s41598-021-81944-8","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T16:02:53Z","timestamp":1613836973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Modified conditioning regimen with idarubicin followed by autologous hematopoietic stem cell transplantation for invasive B-cell non-Hodgkin\u2019s lymphoma patients"],"prefix":"10.1038","volume":"11","author":[{"given":"Chen","family":"Tian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zehui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yizhuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongliang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tian","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"key":"81944_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334. https:\/\/doi.org\/10.3322\/caac.21551 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"81944_CR2","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2141.2005.05603.x","volume":"130","author":"KM Ardeshna","year":"2005","unstructured":"Ardeshna, K. M. et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br. J. Haematol. 130, 363\u2013372. https:\/\/doi.org\/10.1111\/j.1365-2141.2005.05603.x (2005).","journal-title":"Br. J. Haematol."},{"key":"81944_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1002\/cncr.32526","volume":"126","author":"EC Ayers","year":"2020","unstructured":"Ayers, E. C. et al. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. Cancer 126, 293\u2013303. https:\/\/doi.org\/10.1002\/cncr.32526 (2020).","journal-title":"Cancer"},{"key":"81944_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbmt.2007.11.013","volume":"14","author":"T Seshadri","year":"2008","unstructured":"Seshadri, T., Kuruvilla, J., Crump, M. & Keating, A. Salvage therapy for relapsed\/refractory diffuse large B cell lymphoma. Biol. Blood Marrow Transplant. 14, 259\u2013267. https:\/\/doi.org\/10.1016\/j.bbmt.2007.11.013 (2008).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"81944_CR5","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip, T. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 333, 1540\u20131545. https:\/\/doi.org\/10.1056\/NEJM199512073332305 (1995).","journal-title":"N. Engl. J. Med."},{"key":"81944_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/195484","author":"M Gunnellini","year":"2012","unstructured":"Gunnellini, M., Emili, R., Coaccioli, S. & Marina, L. A. The role of autologous stem cell transplantation in the treatment of diffuse large B-cell lymphoma. Adv. Hematol. https:\/\/doi.org\/10.1155\/2012\/195484 (2012).","journal-title":"Adv. Hematol."},{"key":"81944_CR7","doi-asserted-by":"publisher","first-page":"CD004024","DOI":"10.1002\/14651858.CD004024","volume":"23","author":"A Greb","year":"2008","unstructured":"Greb, A. et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma (NHL) in adults. Cochrane Database Syst. Rev. 23, CD004024. https:\/\/doi.org\/10.1002\/14651858.CD004024 (2008).","journal-title":"Cochrane Database Syst. Rev."},{"key":"81944_CR8","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.bbmt.2015.02.005","volume":"21","author":"YB Chen","year":"2015","unstructured":"Chen, Y. B. et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 21, 1046\u20131053. https:\/\/doi.org\/10.1016\/j.bbmt.2015.02.005 (2015).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"81944_CR9","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1016\/j.bbmt.2018.05.018","volume":"24","author":"J Olivieri","year":"2018","unstructured":"Olivieri, J. et al. A comparison of the conditioning regimens BEAM and FEAM for autologous hematopoietics stem cell transplantation in lymphoma: an observational study on 1038 patients from fondazione Italiana Linfomi. Biol. Blood Marrow Transplant. 24, 1814\u20131822. https:\/\/doi.org\/10.1016\/j.bbmt.2018.05.018 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"81944_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1093\/annonc\/mdt029","volume":"24","author":"D Villa","year":"2013","unstructured":"Villa, D. et al. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann. Oncol. 24, 1603\u20131609. https:\/\/doi.org\/10.1093\/annonc\/mdt029 (2013).","journal-title":"Ann. Oncol."},{"key":"81944_CR11","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1007\/s00277-019-03667-1","volume":"98","author":"J Hyung","year":"2019","unstructured":"Hyung, J. et al. Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma. Ann. Hematol. 98, 1657\u20131664. https:\/\/doi.org\/10.1007\/s00277-019-03667-1 (2019).","journal-title":"Ann. Hematol."},{"key":"81944_CR12","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1200\/JCO.2009.22.2554","volume":"27","author":"LE Damon","year":"2009","unstructured":"Damon, L. E. et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909. J. Clin. Oncol. 27, 6101\u20136108. https:\/\/doi.org\/10.1200\/JCO.2009.22.2554 (2009).","journal-title":"J. Clin. Oncol."},{"key":"81944_CR13","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1182\/blood-2014-08-596668","volume":"124","author":"G Visani","year":"2014","unstructured":"Visani, G. et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood 124, 3029\u20133031. https:\/\/doi.org\/10.1182\/blood-2014-08-596668 (2014).","journal-title":"Blood"},{"key":"81944_CR14","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.bbmt.2016.03.018","volume":"22","author":"CR Flowers","year":"2016","unstructured":"Flowers, C. R. et al. Efficacy of pharmacokinetics-directed busulfan, cyclophosphamide, and etoposide conditioning and autologous stem cell transplantation for lymphoma: comparison of a multicenter phase II study and CIBMTR outcomes. Biol. Blood Marrow Transplant 22, 1197\u20131205. https:\/\/doi.org\/10.1016\/j.bbmt.2016.03.018 (2016).","journal-title":"Biol. Blood Marrow Transplant"},{"key":"81944_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s00277-007-0360-0","volume":"87","author":"JC Jo","year":"2008","unstructured":"Jo, J. C. et al. BEAC or BEAM highdose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin\u2019s lymphoma patients: comparative analysis of efficacy and toxicity. Ann. Hematol. 87, 43\u201348. https:\/\/doi.org\/10.1007\/s00277-007-0360-0 (2008).","journal-title":"Ann. Hematol."},{"key":"81944_CR16","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41409-018-0196-3","volume":"53","author":"SP Robinson","year":"2018","unstructured":"Robinson, S. P. et al. High-dose therapy with BEAC conditioning compared to BEAM conditioning prior to autologous stem cell transplantation for non-Hodgkin lymphoma: no differences in toxicity or outcome. A matched-control study of the EBMT-Lymphoma Working Party. Bone Marrow Transplant. 53, 1553\u20131559. https:\/\/doi.org\/10.1038\/s41409-018-0196-3 (2018).","journal-title":"Bone Marrow Transplant."},{"key":"81944_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/10428199709055588","volume":"24","author":"A Engert","year":"1997","unstructured":"Engert, A. et al. A phase-II study with idarubicin, ifosfamide and VP-16 (IIVP-16) in patients with refractory or relapsed aggressive and high grade non-Hodgkin\u2019s lymphoma. Leuk. Lymphoma 24, 513\u2013522. https:\/\/doi.org\/10.3109\/10428199709055588 (1997).","journal-title":"Leuk. Lymphoma"},{"key":"81944_CR18","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/17474086.2017.1318053","volume":"10","author":"M Jiang","year":"2017","unstructured":"Jiang, M., Bennani, N. N. & Feldman, A. L. Lymphoma classification update: B-cell non-Hodgkin lymphomas. Expert Rev. Hematol. 10, 405\u2013415. https:\/\/doi.org\/10.1080\/17474086.2017.1318053 (2017).","journal-title":"Expert Rev. Hematol."},{"key":"81944_CR19","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1097\/01.coc.0000145984.39639.0d","volume":"28","author":"H Abali","year":"2005","unstructured":"Abali, H. et al. IIVP salvage regimen induces high response rates in patients with relapsed lymphoma before autologous stem cell transplantation. Am. J. Clin. Oncol. 28, 264\u2013269. https:\/\/doi.org\/10.1097\/01.coc.0000145984.39639.0d (2005).","journal-title":"Am. J. Clin. Oncol."},{"key":"81944_CR20","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bbmt.2005.05.014","volume":"11","author":"B Oyan","year":"2005","unstructured":"Oyan, B. et al. Ifosfamide, idarubicin, and etoposide in relapsed\/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation. Biol. Blood Marrow Transplant. 11, 688\u2013697. https:\/\/doi.org\/10.1016\/j.bbmt.2005.05.014 (2005).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"81944_CR21","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1016\/j.bbmt.2005.05.014","volume":"32","author":"B Cheson","year":"2014","unstructured":"Cheson, B. et al. Recommendations for initial evaluation, staging and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068. https:\/\/doi.org\/10.1016\/j.bbmt.2005.05.014 (2014).","journal-title":"J. Clin. Oncol."},{"key":"81944_CR22","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1182\/blood.V77.7.1587.1587","volume":"77","author":"T Philip","year":"1991","unstructured":"Philip, T. et al. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation. Blood 77, 1587\u20131592 (1991).","journal-title":"Blood"},{"key":"81944_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/bmt.2017.206","volume":"53","author":"P Galieni","year":"2018","unstructured":"Galieni, P. et al. Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 53, 91\u201393. https:\/\/doi.org\/10.1038\/bmt.2017.206 (2018).","journal-title":"Bone Marrow Transplant."},{"key":"81944_CR24","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1200\/JCO.2000.18.16.3025","volume":"18","author":"C Haioun","year":"2000","unstructured":"Haioun, C. et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin\u2019s lymphoma: final analysis of the prospective LNH87-2 protocol-a grouped\u2019Etude des lymphomes de l\u2019Adulte study. J. Clin. Oncol. 18, 3025\u20133030. https:\/\/doi.org\/10.1200\/JCO.2000.18.16.3025 (2000).","journal-title":"J. Clin. Oncol."},{"key":"81944_CR25","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","volume":"18","author":"A Chiappella","year":"2017","unstructured":"Chiappella, A. et al. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised,controlled, phase 3 study. Lancet Oncol. 18, 1076\u20131088. https:\/\/doi.org\/10.1016\/S1470-2045(17)30444-8 (2017).","journal-title":"Lancet Oncol."},{"key":"81944_CR26","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","volume":"369","author":"S Patrick","year":"2013","unstructured":"Patrick, S. et al. Autologous transplantation as consolidation for aggressive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 369, 1681\u20131690. https:\/\/doi.org\/10.1056\/NEJMoa1301077 (2013).","journal-title":"N. Engl. J. Med."},{"key":"81944_CR27","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/sj.bmt.1702795","volume":"27","author":"A Salar","year":"2001","unstructured":"Salar, A. et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin\u2019s lymphoma: the role of preparative regimens. Bone Marrow Transplant. 27, 405\u2013412. https:\/\/doi.org\/10.1038\/sj.bmt.1702795 (2001).","journal-title":"Bone Marrow Transplant."},{"key":"81944_CR28","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1111\/ajco.12610","volume":"13","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. Comparison of CBV, BEAM and BEAC high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non-Hodgkin lymphoma: efficacy and toxicity. Asia Pac. J. Clin. Oncol. 13, e423\u2013e429. https:\/\/doi.org\/10.1111\/ajco.12610 (2017).","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"81944_CR29","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1365-2141.2012.09174.x","volume":"158","author":"CH Geisler","year":"2012","unstructured":"Geisler, C. H. et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br. J. Haematol. 158, 355\u2013362. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09174.x (2012).","journal-title":"Br. J. Haematol."},{"key":"81944_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41409-018-0395-y","volume":"54","author":"I Sakellari","year":"2019","unstructured":"Sakellari, I. et al. BEAC (carmustine, etoposide, cytarabine, and cyclophosphamide) in autologous hematopoietic cell transplantation: a safe and effective alternative conditioning regimen for Hodgkin and non-Hodgkin lymphoma. Bone Marrow Transplant. 54, 921\u2013923. https:\/\/doi.org\/10.1038\/s41409-018-0395-y (2019).","journal-title":"Bone Marrow Transplant."},{"key":"81944_CR31","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1111\/j.1600-0609.2006.00687.x","volume":"77","author":"T Kuittinen","year":"2006","unstructured":"Kuittinen, T. et al. Cardiac effects within 3 months of BEAC high-dose therapy in non-Hodgkin\u2019s lymphoma patients undergoing autologous stem cell transplantation. Eur. J. Haematol. 77, 120\u2013127. https:\/\/doi.org\/10.1111\/j.1600-0609.2006.00687.x (2006).","journal-title":"Eur. J. Haematol."},{"key":"81944_CR32","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/cncr.23861","volume":"113","author":"E Derenzini","year":"2008","unstructured":"Derenzini, E. et al. Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma. Cancer 113, 2496\u20132503. https:\/\/doi.org\/10.1002\/cncr.23861 (2008).","journal-title":"Cancer"},{"key":"81944_CR33","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1182\/blood-2014-10-606939","volume":"125","author":"CS Sauter","year":"2015","unstructured":"Sauter, C. S. et al. Prognostic value of FDG-PET prior to autologous stem cell transplantation for relapsed and refractory diffuse large B-cell lymphoma. Blood 125, 2579\u20132581. https:\/\/doi.org\/10.1182\/blood-2014-10-606939 (2015).","journal-title":"Blood"},{"key":"81944_CR34","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1080\/10428194.2016.1185785","volume":"57","author":"A Isidori","year":"2016","unstructured":"Isidori, A., Christofides, A. & Visani, G. Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed\/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning. Leuk. Lymphoma 57, 2499\u20132509. https:\/\/doi.org\/10.1080\/10428194.2016.1185785 (2016).","journal-title":"Leuk. Lymphoma"},{"key":"81944_CR35","doi-asserted-by":"publisher","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","volume":"91","author":"DD Von Hoff","year":"1979","unstructured":"Von Hoff, D. D. et al. Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med. 91, 710\u2013717. https:\/\/doi.org\/10.7326\/0003-4819-91-5-710 (1979).","journal-title":"Ann. Intern. Med."},{"key":"81944_CR36","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1200\/JCO.2004.06.033","volume":"22","author":"O Hequet","year":"2004","unstructured":"Hequet, O. et al. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J. Clin. Oncol. 22, 1864\u20131871. https:\/\/doi.org\/10.1200\/JCO.2004.06.033 (2004).","journal-title":"J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81944-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81944-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T03:52:36Z","timestamp":1670039556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81944-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81944"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81944-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"type":"electronic","value":"2045-2322"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"31 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4273"}}